Two major US drugstore chains to combine - EXPO
Transcription
Two major US drugstore chains to combine - EXPO
THURSDAY, OCTOBER 29, 2015 I Bangkok Post WORLD BUSINESS I B7 Two major US drugstore chains to combine Walgreens pays $9.4bn for smaller rival Rite Aid MICHAEL J. de la MERCED HIROKO TABUCHI Pedestrians walk past a Rite Aid store in Oakland, California in this April 1, 2015, file photo. REUTERS technology Apple profit jumps 31% as iPhones sell briskly KATIE BENNER New York: Apple Inc on Tuesday turned in another quarter of enviable revenue and profit growth, fueled by sales of the iPhone. But the results raised a perennial question for the world’s most valuable company: How can it keep its growth streak alive? The issue was stoked by Apple’s muted forecast for its all-important holiday quarter, as well as the unwillingness of Timothy D. Cook, the company’s chief executive, to go into detail in an earnings conference call about how Apple plans to rev up sales next year. Overall, Apple posted a profit of $11.1 billion for its fiscal fourth quarter, up 31% from a year ago. Revenue was $51.5 billion, up 22% from last year. The results exceeded Wall Street estimates. Yet while the performance was bolstered by sales of the iPhone — Apple said that it sold 48 million iPhones in the quarter, up from 39 million in the same period last year — the company was more cautious about sales for the key holiday sales period. Apple projected revenue of $75.5 billion to $77.5 billion for the end-of-year quarter. While the sheer numbers are huge, the low end of the forecast fell below Wall Street estimates and would amount to anemic growth of less than 4% from a year ago. The last time Apple’s quarterly sales fell below 4% was in mid-2013. When asked on the earnings call about Apple’s growth prospects in 2016, Cook also said, “We don’t guide beyond a quarter.” The growth question is a quandary created by Apple’s own success. The company has gotten investors accustomed to double-digit growth rates and enormous profit. That sets a high bar for Apple to clear each time and creates tough comparisons to beat later. Cook for the most part shrugged off the growth question. In the conference call, he said Apple’s full fiscal year revenue was equivalent to that of almost 90% of the companies in the Fortune 500. Apple delivered “a strong finish to a very strong year,” even with a strong dollar that has forced the company to raise prices in many of its markets around the world, Cook said. Apple is going into 2016 with a full slate of refreshed products. In late September, the company introduced its newest iPhone models, the 6s and 6s Plus. It also announced a larger iPad, the iPad Pro, and will begin shipping a new Apple TV this week. While the iPhone continues to grow, the iPad has been facing declines. For the fiscal fourth quarter, Apple said iPad sales dropped 20% from a year ago, making it the seventh consecutive quarter that sales of the tablet have slipped. The company did not break out sales of the Apple Watch, which debuted in April. But the category called “other products” — which includes the watch — posted $3 billion in revenue in the quarter, up from $2.6 billion in the previous quarter, which was the first quarter that included sales of the device. Ben Bajarin, an analyst at Creative Strategies, said that the numbers for the “other” category were in line with his expectations, and implied somewhere between 3.5 million and four million watches were sold over the quarter. ©2015 The New York Times New York: As companies throughout the universe of the healthcare industry accelerate the pace of consolidation, two of the biggest drugstore chains in the Unites States have agreed to combine to create a new giant. Walgreens Boots Alliance Inc said on Tuesday that it would buy Rite Aid Corp for more than $9.4 billion in cash, significantly bolstering its influence with drugmakers and pharmacy benefit managers. But the combination may draw a sceptical eye from government regulators concerned about the retail pharmacy market effectively shrinking to only a few big chains. The deal is the latest taking place in the sweeping changes under the Affordable Care Act, which has inspired drug makers, insurers and others to combine. For pharmacies, a rise in insured Americans has increased prescription demand, helping increase the total revenue of the nation’s retail, mail and specialty pharmacies 7% last year from 2013. At the same time, companies have also been pressured to keep costs down. Walgreens Boots Alliance, itself forged in the combination of Walgreen Co and the European chain Alliance Boots, has made no secret of its desire to expand through acquisitions. Led by Stefano Pessina, a trained nuclear engineer and former academic who sold Alliance Boots to its American counterpart, the company has strongly hinted that Rite Aid would be a target. “Today’s announcement is another step in Walgreens Boots Alliance’s global development and continues our profitable growth strategy,” he said. Even before the Alliance Boots deal, Walgreens has kept busy with mergers, acquiring Duane Reade, USA Drugs and Kerr Drug to grow to more than 8,200 stores and revenue of $76 billion last year. Under the terms of the deal announced on Tuesday, Rite Aid shareholders will receive $9 a share — a premium of 48% to its closing stock price Monday. Buying Rite Aid would give Walgreens an additional 4,600 stores in 31 states, adding to its roughly 8,200 locations across the country, Puerto Rico and the Virgin Islands. The biggest drugstore chain by market capitalisation, CVS Health, has also grown, acquiring Long’s Drug, Medicine Chest and Navarro Discount Pharmacy. It now runs more than 7,800 stores. With years of steep losses, Rite Aid, which itself acquired the Brooks and Eckerd pharmacy chains in 2007, has fallen to a distant third. “The pharmacy consolidation endgame has begun,” said Adam J. Fein, president of Pembroke Consulting, a firm based in Philadelphia that specialises in the pharmaceutical industry. “Rite Aid was one of the last remaining pharmacy assets available for purchase.” “Even with its debt, Rite Aid could have survived into the future. But this combination will give the new business a lot more scale,” he said. “The combined entity will have a lot more power against pharmacy benefit managers and other payers. They will be able to negotiate higher reimbursements for prescriptions.” Rite Aid will be a wholly owned subsidiary of Walgreens operating under its own brand name when the deal is completed. Yet the transaction, which is expected to close by the end of next year, could draw significant antitrust scrutiny. Regulators will study specific geographical areas where Walgreens and Rite Aid compete, according to Jeffrey S. Spigel, the head of the antitrust practice at the law firm King & Spalding. The combined new business will most likely need to divest itself of overlapping locations. “The FTC is also likely to scrutinise the changing ways in which consumers buy pharmacy items and prescriptions, and assess whether there is ample competition for these products,’’ Spigel said. “I expect that the companies will argue that the competition is now broader than just the Rite Aids, Walgreens and CVSs of the world,” he said. “They’ll argue that you need to take into account competition from pharmacies that are in grocery stores, that are in Wal-Marts, that sell through mail order.” ©2015 The New York Times defence industry Bomber contract gives Northrop financial lifeline Richard Clough Tony Capaccio New York/Washington: Northrop Grumman Corp, shut out of prime contracts for US warplanes since the B-2 in the 1980s, on Tuesday won a Pentagon sweepstakes valued at as much as $80 billion to build the Air Force’s Long-Range Strike Bomber. In beating a team of Lockheed Martin Corp and Boeing Co, Northrop overcame the world’s two largest defence contractors and secured a financial lifeline stretching into the 2020s. The plane, still highly classified after years of planning, will be the military’s first new bomber since the Cold War and one of the biggest US weapons systems of the next decade. “There was a David and Goliath situation going on,” said Richard Aboulafia, an analyst at consultant Teal Group. “This is disappointing for Lockheed Martin, pretty bad for Boeing, but transformational for Northrop Grumman. They go from being a collection of operating units to a first-tier prime with a strong central core.” Lockheed and Boeing, which both have other warplanes in service or under development, worked together on their bid for the Long-Range Strike Bomber. The new plane will join the B-2 and is due to enter service in the mid-2020s as the successor to the 37-year-old B-1 and the Eisenhower-era B-52. The Air Force wants aviation Delta parts company with US airline trade group New York/Dallas: Delta Air Lines Inc will leave the US industry’s main trade group in 2016 after the world’s third-largest carrier staked out policy differences with several of its peers. The move was not unexpected as the carrier has not been aligned with other members of Washington-based Airlines for America (A4A), the group’s chief executive officer, Nick Calio, said in a statement on Tuesday. Delta didn’t agree with the group’s support for reorganising the US air traffic control system and removing it from federal oversight, A4A said. Delta’s exit underscores the gap among US airlines over competition from Persian Gulf carriers. The Atlanta-based airline has been the largest source of funds for lobbying against what it says are unfair government subsidies for the Gulf trio — a stance backed by American Airlines Group Inc and United Continental Holdings Inc. JetBlue Airways Corp has supported expansion by the Middle East carriers. “It makes some sense,” said George Hamlin, president of Hamlin Transportation Consulting. “You’ve got quite a disparate group. It’s useful to have a trade group, but sometimes you have members going off in different directions.” Delta also has differed with other A4A members over the US Export-Import Bank, lobbying Congress against renewal of the agency that provides low-interest loans to help foreign carriers buy Boeing Co’s wide-body aircraft to compete on international routes. “Delta’s departure, and the loss of about $5 million the airline paid in annual dues, won’t affect the trade group’s staffing or the scope of its work,’’ A4A spokeswoman Jean Medina said in an e-mail. A4A hadn’t taken a strong stance in the Gulf carriers issue given the differing views among its members. Delta, American and United are asking the Obama administration to seek consultations with the United Arab Emirates and Qatar related to the issue as part of the Open Skies agreements the US has with both states. Delta’s annual A4A dues “can be better used to invest in employees and products to further enhance the Delta experience, and to support what we believe is a more efficient way of communicating in Washington on issues that are important to Delta customers and employees,” Kate Modolo, a Delta spokeswoman, said in an e-mailed statement. bloomberg ANA’s first-half profit soars Tokyo: All Nippon Airways said yesterday that its six-month net profit soared 51% as a jump in inbound tourism boosted its international business, while falling oil prices also help airlines’ finances. The airline has been given a lift by an expansion of landing slots at Tokyo’s Haneda Airport, while a weak yen has been drawing record numbers of tourists to Japan. ANA has been in a spat with its rival and one-time flag-carrier Japan Airlines (JAL) over the allocation of landing slots at Haneda, after JAL emerged from one of the nation’s biggest-ever bankruptcies following a government rescue. JAL reports its earnings later this week. Falling oil prices have also helped the carrier’s bottom line — fuel is often an airline’s single-biggest expense. ANA Holdings Inc, the parent company of All Nippon Airways, said its profit in the April-September period was 53.97 billion yen ($448 million), with revenue up nearly seven percent from a year ago. “ANA continued to see a positive impact from the expansion in its international flight slots at Haneda airport at a time when demand for business use is growing steadily,” said Hiroshi Hasegawa, an analyst at SMBC Nikko Securities. “A cut in fuel costs in the wake of falls in crude oil prices also contributed to the profit gain. I’m not seeing any major negative factors for the industry right now, but an economic slump could hurt demand for business class seats in the future.” ANA this summer threw a lifeline to struggling domestic rival Skymark Airlines, Japan’s third-biggest airline, which flies on domestic routes. Skymark filed for bankruptcy protection in late January in the face of potentially massive penalties linked to a cancelled $2.2 billion jet order with Airbus SAS. The Skymark deal would expand ANA’s landing slots and give it the upper hand in setting airfares. In August, Skymark creditors voted in favour of a rescue plan led by ANA, edging out a rival bid that included US carrier Delta Air Lines. ANA is aiming to lure more Chinese tourists to Japan in the second half by boosting flights between Haneda and airports in China, the Nikkei business daily has reported. afp a durable, stealthy aircraft that can fly deep into enemy territory to attack hidden or mobile targets. What that plane will look like is still unknown, at least to the public. A Northrop commercial during the 2015 Super Bowl subtly tried to link its jet — shown as a shrouded flying-wing shape — to the B-2 and other past aviation glories. But there has been no indication whether the new jet will resemble that shape or some other design. “Northrop’s proposal is the best value for our nation,” Air Force secretary Deborah Lee James said at a news conference at the Pentagon. Based on figures released on Tuesday, which exclude the cost of any related future military construction, the bomber programm e calls for spending $23.5 billion in development plus $56 billion on procurement, or about $564 million for each bomber in 2016 dollars. “Northrop has won ‘the’ military aircraft award of the decade, and assuming that it goes to plan this will be a key driver of revenue growth for at least the next 10 years,” Robert Stallard, an RBC Capital analyst, said in a note to clients. He estimated that the programme could add about $1 billion in annual revenue starting in 2018. Howard Rubel, an analyst with Jefferies LLC, projected that the plane could account for as much as 10% of Northrop’s sales — 2014’s total was $24 billion — within a few years. Lockheed and Boeing could choose to protest the award, which typically must happen within two weeks, according to Nick Taborek, an analyst with Bloomberg Intelligence. Given the years of research that went into the decision, the chances of overturning it “are likely even slimmer than the usual 4% success rate,’’ he said in a report. The plane also was of less-urgent financial consequence to Lockheed, the builder of the F-35 fighter, and Boeing, the commercial-and-defence giant whose military programmes include the KC-46 tanker. Together, their revenue is about five times that of Falls Church, Virginia-based Northrop. bloomberg